insights from industryBernd GleixnerDivision President AutomationBruker Biopsin News Medical speaks to Bernd Gleixner, Division President Automation at Bruker Biospin, about the future of lab ...

Every stage of biopharma drug development depends on what happens in the laboratory. Consequently, any one of these stages—which include target identification, lead optimization, candidate screening, ...

NewsMedical talks to Bruker BioSpin about how Chemspeed’s modular automation systems integrate with NMR technology to enable smarter, more autonomous labs. Chemspeed systems are known for their ...

The progress in laboratory automation could be one of the most consistent changes in research in the life sciences and biomedicine over the past 30 years. The evolution of this field borders on the ...

How has technology changed the way we conduct research? Lab automation takes many different forms with the purpose of streamlining several aspects of experiments, data collection and data analysis.

The lab automation market is expected to surpass $8.36 billion globally in 2025 and reach $14.78 billion by 2034. Pharmaceutical and biotech companies are making huge investments in lab automation ...